444 related articles for article (PubMed ID: 30175973)
1. LncRNA CASC2 expression is down- regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway.
Zhou T; Zhong M; Zhang S; Wang Z; Xie R; Xiong C; Lv Y; Chen W; Yu J
Cancer Biomark; 2018; 23(2):185-191. PubMed ID: 30175973
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA CASC2 targeting miR-18a suppresses glioblastoma cell growth, metastasis and EMT
Wang J; Qin C; Zhong C; Wen Y; Ke S; Liao BO
J Biosci; 2020; 45():. PubMed ID: 32975234
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
[TBL] [Abstract][Full Text] [Related]
5. LncRNA RGMB-AS1 is activated by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma.
Zhang Z; Li SY; Zhang LB
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1979-1986. PubMed ID: 29687852
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition.
Song R; Zhang J; Huang J; Hai T
Cancer Biomark; 2018; 22(3):565-573. PubMed ID: 29843220
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of long noncoding RNA SLC26A4-AS1 inhibits the epithelial-mesenchymal transition via the MAPK pathway in papillary thyroid carcinoma.
Wang DP; Tang XZ; Liang QK; Zeng XJ; Yang JB; Xu J
J Cell Physiol; 2020 Mar; 235(3):2403-2413. PubMed ID: 31556116
[TBL] [Abstract][Full Text] [Related]
8. LncRNA-HCG18 regulates the viability, apoptosis, migration, invasion and epithelial-mesenchymal transition of papillary thyroid cancer cells via regulating the miR-106a-5p/PPP2R2A axis.
Zhu Y; Zhao J; Tan L; Lin S; Long M; Peng X
Pathol Res Pract; 2021 May; 221():153395. PubMed ID: 33798913
[TBL] [Abstract][Full Text] [Related]
9. lncRNA CASC2 Enhances
Tao L; Tian P; Yang L; Guo X
Biomed Res Int; 2020; 2020():7183629. PubMed ID: 33134385
[TBL] [Abstract][Full Text] [Related]
10. Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer.
Xue Z; Zhu X; Teng Y
Mol Med Rep; 2018 Dec; 18(6):5173-5181. PubMed ID: 30320385
[TBL] [Abstract][Full Text] [Related]
11. Silencing SIX1 inhibits epithelial mesenchymal transition through regulating TGF-β/Smad2/3 signaling pathway in papillary thyroid carcinoma.
Min WP; Wei XF
Auris Nasus Larynx; 2021 Jun; 48(3):487-495. PubMed ID: 33077306
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer.
Li Y; Su X; Pan H
Cancer Biomark; 2019; 25(2):185-192. PubMed ID: 31104011
[TBL] [Abstract][Full Text] [Related]
13. microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway.
Wang DP; Tang XZ; Liang QK; Zeng XJ; Yang JB; Xu J
J Cell Physiol; 2020 Mar; 235(3):2492-2505. PubMed ID: 31565805
[TBL] [Abstract][Full Text] [Related]
14. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA CASC2 inhibits metastasis and epithelial to mesenchymal transition of lung adenocarcinoma via suppressing SOX4.
Wang D; Gao ZM; Han LG; Xu F; Liu K; Shen Y
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4584-4590. PubMed ID: 29131257
[TBL] [Abstract][Full Text] [Related]
16. High expression of LINC0163 promotes progression of papillary thyroid cancer by regulating epithelial-mesenchymal transition MITF.
Gao P; Jiao H; Zhe L; Cui J
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5504-5511. PubMed ID: 32495885
[TBL] [Abstract][Full Text] [Related]
17. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212.
Wang R; Zhao L; Ji L; Bai L; Wen Q
Biomed Pharmacother; 2019 Oct; 118():109298. PubMed ID: 31404776
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
19. LncRNA PROX1-AS1 promotes proliferation, invasion, and migration in papillary thyroid carcinoma.
Shen Y; Xia E; Bhandari A; Wang X; Guo G
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061172
[TBL] [Abstract][Full Text] [Related]
20. LncRNA FAM230B promotes the metastasis of papillary thyroid cancer by sponging the miR-378a-3p/WNT5A axis.
Zhou Q; Feng J; Yin S; Ma S; Wang J; Yi H
Biochem Biophys Res Commun; 2021 Mar; 546():83-89. PubMed ID: 33578293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]